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Cutaneous melanoma carries the potential for substantial morbidity and mortality in the solid organ transplant
population. We systematically reviewed the literature published from January 1995 to January 2012 to determine
the overall relative risk and prognosis of melanoma in transplant recipients. Our search identified 7,512 citations.
Twelve unique non-overlapping studies reported the population-based incidence of melanoma in an inception
cohort of solid organ transplant recipients. Compared to the general population, there is a 2.4-fold (95% confidence
interval, 2.0 to 2.9) increased incidence of melanoma after transplantation. No population-based outcome data were
identified for melanoma arising post-transplant. Data from non-population based cohort studies suggest a worse
prognosis for late-stage melanoma developing after transplantation compared with the general population. For
patients with a history of pre-transplant melanoma, one population-based study reported a local recurrence rate
of 11% (2/19) after transplantation, although staging and survival information was lacking. There is a need for
population-based data on the prognosis of melanoma arising pre- and post-transplantation. Increased incidence
and potentially worse melanoma outcomes in this high-risk population have implications for clinical care in terms
of prevention, screening and reduction of immunosuppression after melanoma development post-transplant, as
well as transplantation decisions in patients with a history of pre-transplant melanoma.
Keywords: Melanoma, Cancer, Malignancy, Neoplasia, Transplant, Incidence, Prognosis, Registry, EpidemiologyIntroduction
Important advances in solid organ transplantation have
led to improved patient survival over recent decades.
With prolonged survival, the long-term complications of
immunosuppressive therapy have become increasingly
important. Decreased immune surveillance after transplant
leads to a three- to fourfold increased risk of malignancy
compared to the general population [1,2].
Skin cancer is the most common form of post-transplant
malignancy, particularly squamous cell carcinoma (relative
risk 14 to 82) [3-6]. Although the incidence of melanoma
is increased to a lesser degree than for squamous cell car-
cinoma, the potential for melanoma metastasis can intro-
duce significant morbidity and mortality. Previous studies* Correspondence: erinjadedahlke@gmail.com
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unless otherwise stated.of melanoma in the transplant population have often had
low numbers of cases, which precludes precise estimation
of relative risk and produces variable estimates across stud-
ies. In addition, data on clinical outcomes such as metasta-
sis or mortality are scarce for melanoma arising pre- and
post-transplantation.
With its increased incidence and significant metastatic
potential, melanoma has important implications for the
care of transplant recipients. We aim to systematically
review the published literature to determine the overall
relative risk and prognosis of melanoma in solid organ
transplant recipients.Materials and methods
On 12 January 2012, electronic literature searches were
conducted in Ovid MEDLINE (1946 to week 1 of January
2012, and In-Process and Other Non-Indexed Citations
from 1946 to the present) and EMBASE (1980 to week 2
of 2012) to identify eligible studies using a comprehensive
search strategy developed in consultation with an informa-
tion specialist. The search terms consisted of the following:Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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anoma (expanded), and transplant (organ/kidney/renal/
heart/cardiac/liver/hepat/lung/pulmonary/pancreas/in-
testine/spleen) and cohort/incidence/prevalence/prognosis.
Studies were limited to those published after 1995 in
English and French. We included studies that estimated
the relative risk or reported clinical outcomes (stage,
recurrence, metastasis or death) of melanoma in a
population-based inception cohort of solid organ trans-
plant recipients (kidney, liver, heart, lung, pancreas or in-
testine). Studies were not excluded based on a quality
assessment.
We initially screened all titles and abstracts to exclude
articles that were clearly ineligible. We then reviewed
full-text articles for all remaining citations. Reference
lists from relevant articles were also reviewed for rele-
vant articles. When needed, we obtained additional data
from the study authors by email correspondence. If there
were studies with more than a 50% overlap in their pa-
tient populations (based on country, year of transplant,
type of graft and data source), we included data from
only the most recent or inclusive study.Figure 1 Flow diagram.We pre-specified three main systematic review outcomes:
the incidence and relative risk of melanoma diagnosed after
solid organ transplantation compared to the general po-
pulation; the outcomes of melanoma diagnosed after
solid organ transplantation (post-transplant melanoma), in-
cluding recurrence, metastasis and mortality (overall and
melanoma-specific); and the outcomes of melanoma diag-
nosed prior to transplantation (pre-transplant melanoma).
For articles reporting incidence data, the pooled stan-
dardized incidence ratio (SIR) and 95% confidence interval
(CI) were calculated using weights from a random effects
model. The variation in effect sizes attributable to hete-
rogeneity was quantified using the I-squared statistic. To
explore potential sources of heterogeneity, we used meta-
regression to adjust for the graft organ type (renal/liver
versus heart/lung) and the most recent year of transplant-
ation included in the study cohort (>2000 versus ≤2000).
All statistical analyses were performed using Stata 12.1.
Results
The literature search identified 4,093 citations from Ovid
MEDLINE and 6,311 from EMBASE. After removing
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eliminated 7,369 citations based on title or abstract. A
full-text review of the remaining 143 articles led to the
further exclusion of 125 articles, most commonly because
the studies were not population-based (Figure 1).
We identified 17 studies that reported the incidence of
melanoma in a population-based cohort of solid organ
transplant recipients [3-19]. No eligible studies of post-
transplant melanoma outcomes were found. One popula-
tion-based study reported the outcomes of pre-transplant
melanoma. We requested and obtained additional infor-
mation from the primary author for two studies through
email correspondence [12,20]. (Y Jiang, MD, 7 March
2011, and J Brewer, MD, 24 February 2012).
Incidence of post-transplant melanoma
Among the 17 population-based studies reporting mel-
anoma incidence after transplant, five were excluded to
avoid double counting of data that overlapped signifi-
cantly with other studies [11,14,15,17,18]. Two Swedish
studies collected data from the Swedish National In-
patient Registry for patients transplanted between 1970
and 1994 [14] and between 1970 and 1997 [6]; we exclu-
ded the older cohort. A Norwegian study that reported
skin cancer incidence in heart and renal transplant
recipients [15] was excluded due to significant overlap
with a larger study [10] that reported cancer risk after
renal transplantation in all Nordic countries. We ex-
cluded two Australian [17,18] studies that overlapped
with a more recent study of a larger cohort of renal
transplant recipients in Australia and New Zealand [7]. Fi-
nally, two studies from the United States used overlappingTable 1 Characteristics of 12 included studies reporting relati
First author (publication year) Country Graft type
Jiang [8] Canada Heart
Webster [7] Australia, New Zealand Renal
Birkeland [10] Nordica Renal
Villeneuve [16] Canada Renal
Moloney [3] Ireland Renal
Bastiaannet [9] Netherlands Renal
Aberg [13] Finland Liver
Jiang [12] Canada Liver
Adami [6] Sweden Renal, liver, hea
Jensen [5] Denmark Renal, liver, hea
Collett [4] United Kingdom Renal, liver, hea
Engels [19] United States Renal, liver, hea
aDenmark, Finland, Norway and Sweden.datasets; we included the more recent and inclusive
study [11,19].
Characteristics of the 12 included studies are listed in
Table 1. The study populations were for kidney (N = 5),
liver (N = 2), heart (N = 1) and various solid organ trans-
plants (N = 4) performed in North America, Europe,
Australia and New Zealand. There was less than 50%
overlap of populations in three included studies from
Sweden [6], Denmark [5] and the Nordic countries [10].
Regional cancer registries were the main data source
for identifying melanoma diagnoses. All studies reported
rates of melanoma in transplant recipients compared to
their respective age-, sex- and time-matched general
population rates. One study also accounted for race [19].
Overall, transplant recipients have a pooled estimate
of 2.4 times (95% confidence interval, 2.0 to 2.9) the
risk of melanoma compared to the general population
(Figure 2). The overall I-squared was 46% (P = 0.04),
indicating moderate heterogeneity between studies.
Adjusting for the type of organ graft and the most recent
year of transplant in the cohort reduced the I-squared
value to 0%. Studies of renal or liver transplant recipi-
ents had an absolute increase in SIR of 0.29 compared
to studies that included heart or lung transplant recipi-
ents (P = 0.01). Studies that included patients trans-
planted after the year 2000 had an increase in SIR of
0.41 compared to older studies (P = 0.03).
Prognosis of post-transplant melanoma
Our search identified no population-based studies re-
porting data on outcomes of de novo melanoma arising
post-transplantation. We identified ten retrospective,ve incidence of post-transplant melanoma
Transplant years Population size Follow-up time
1981–1998 1,703 10,369 person-years
1963–2004 15,183 130,186 person-years;
median 7.2 years
1964–1982 5,692 32,392 person-years
1981–1998 11,033 81,237 person-years
1986–2001 1,558 Median 5.7 years
1989–2003 1,125 8165 person-years;
mean 7.3 years
1982–2005 540 3222 person-years;
mean 6.3 years
1983–1998 2,034 10,371 person-years
rt, lung 1970–1997 5,931 40,360 person-years;
mean 6.8 years
rt, lung 1977–2006 5,279 35,615 person-years;
median 5 years
rt, lung 1980–2007 37,617 Median 16 years
rt, lung 1987–2008 175,732 775,147 person-years
Figure 2 Forest plot of standardized incidence ratios for 12 included studies. CI, confidence interval; SIR, standardized incidence ratio.
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from various sources [20-29]. As many of these papers
present overlapping data, the most summative articles
are described in Table 2.
In the largest study reporting on post-transplant mel-
anoma outcomes, Brewer et al. retrospectively identified
638 cases of post-transplant melanoma in the United
States collected from three Mayo Clinic databases (Florida,
Rochester and Arizona), the Organ Procurement Trans-
plant Network (OPTN) and the Israel Penn International
Tumor Transplant Registry (IPITTR). They found that
overall survival rates were worse in the transplant popula-
tion compared to the general population based on Surveil-
lance, Epidemiology and End Results (SEER) data. In
particular, patients with melanomas with a Breslow depth
of 1.51 to 3.00 mm and Clark levels III/IV had significantly
worse outcomes compared with the expected survival
rates in the general population [20]. A number of earlier
publications also reported from these same databases
[25,27-29].
In the second largest non-overlapping study, Matin
et al. reported worse outcomes for late stage (T3/T4)
melanoma in transplant recipients compared to the
general population [26]. This group analyzed cases from
the Skin Care in Organ Transplant Patients, Europe
network (SCOPE) database, which collects data from 14
transplant dermatology clinics. They compared 81 cases
of melanoma in transplant patients to controls matchedby age, sex, tumor thickness and ulceration, and found
worse outcomes in transplant patients with stage T3/T4
tumors (>2 mm thick). They found outcomes similar
to the controls for early stage (T1/T2) melanomas.
The hazard ratio for T3/T4 stage tumors was 11.49
(3.6 to 36.8).
Frankenthaler et al. reported on outcomes of 19 melan-
oma patients who were taking immunosuppressive therap-
ies for renal transplantation (4 patients) or autoimmune
conditions (15 patients). Each case was matched to three
non-immunosuppressed controls with a similar age, sex,
stage and location of primary tumor. They found no sig-
nificant difference in relapse rates but worse overall sur-
vival in the immunosuppressed group, suggesting a more
aggressive clinical course [21]. Other smaller, uncontrolled
cohort studies have shown variable findings (Table 2).
Post-transplantation prognosis of pre-transplant melanoma
Our search identified one population-based, retrospective,
uncontrolled cohort study reporting on post-transplant
outcomes of melanoma diagnosed prior to solid organ
transplantation (Table 3) [30]. Chapman et al. reported
data on cancers (excluding non-melanoma skin cancers)
diagnosed before renal transplantation that subsequently
recurred post-transplant. From the Australian and New
Zealand Dialysis and Transplant Registry (ANZDATA), 19
of 11,894 patients who received renal transplants from
1963 to 1999 had a history of pre-transplant melanoma.
















638 AJCC pathologic stage
(67 tumors)
Worse 3-year, cause-specific survival
for Breslow 1.51 to 3.0 mm and








4 (renal transplant) AJCC stage (19) Similar relapse rates but worse
overall survival in immunosuppressed
group versus controls.15 (autoimmune disease)
Similar stage distribution at diagnosis
compared to general melanoma database.
Matin [26] Europe SCOPE, AJCC 89 Breslow depth (83) Worse overall survival for Breslow >2 mm
in transplant patients versus controls
(HR 11.5, 95% CI 3.6 to 36.8), but not
found for Breslow ≤2 mm (HR 1.5,
95% CI 0.31 to 6.9).
Clark level (82)
Ulceration (79)
14 patients with metastasis.




10 Breslow depth (10) 1 patient died from metastatic
melanoma (Breslow 4.5 mm).Clark level (10)
Ulceration (10) No recurrence in other cases (all
<1 mm).




4 deaths from metastasis.
Lévêque [24] France 9 centers 17 Breslow depth (16) 4 deaths from metastasis
Clark level (16)
Ulceration (16)
aOverlap with three prior studies [25,27,28].
AJCC, American Joint Committee on Cancer; BIDMC, Beth Israel Deaconess Medical Center; CI, confidence interval; HR, hazard ratio; IPITTR, Israel Penn International
Transplant Tumor Registry (previously Cincinnati transplant tumor registry); OPTN, Organ Procurement and Transplantation Network; SCOPE, Skin Care in Organ
Transplant Patients, Europe.
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rence after transplant. No data on staging or post-trans-
plant metastasis were available.
We also identified two non-population based, retro-
spective, uncontrolled cohort studies (Table 3) [20,26].
Brewer et al. examined the post-transplant outcomes of
59 cases of pre-transplant melanoma collected from the











Chapman [30] Yes Australia,
New Zealand
ANZDATA 1






Matin [26] No Europe SCOPE network
(14 clinics)
9
aOverlap with two prior studies [25,28].
ANZDATA, Australian and New Zealand Dialysis and Transplant Registry; IPITTR, Isra
and Transplantation Network; SCOPE, Skin Care in Organ transplant Patients, Europdepth was available for a subset of 17 cases. They repor-
ted no recurrences and two melanoma metastases with a
mean follow up of 10.5 years. This study encompassed
data from two previous reports [25,28], including data
from IPITTR that originally suggested that 6 of 31
patients with pre-transplant melanoma died from post-
transplant recurrences [28]. However, these findings









9 Not available Recurrence (2)
9 Breslow depth (15) Median post-melanoma




Breslow depth (6) No deaths after median
post-melanoma follow-up
of 14 years
el Penn International Transplant Tumor Registry; OPTN, Organ Procurement
e; SEER, Surveillance, Epidemiology and End Results.
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not histopathologically confirmed (personal communica-
tion, J Brewer, MD, 24 February 2012).
Matin et al. reported data voluntarily provided by
physicians in the SCOPE network database (Table 3).
Breslow depth was available for six of nine patients with
pre-transplant melanoma. No post-transplant deaths were
noted after 3.3 to 42 years of post-melanoma follow-up
(median 14 years) and 0.5 to 10.2 years of post-transplant
follow-up (median 5 years) [26].
Discussion
This is the first systematic review of melanoma inci-
dence and outcomes in the solid organ transplant popu-
lation. Compared to the general population, there is a
2.4-fold increased incidence of melanoma in the trans-
plant population. No population-based outcome data
were identified for melanoma arising post-transplant.
Data from non-population-based cohort studies suggest
a worse prognosis for late-stage melanoma developing in
a transplant population versus a general population. For
melanoma arising prior to transplantation, one uncon-
trolled population-based study found an 11% local recur-
rence rate post-transplant, although staging and survival
data were lacking.
Immune function plays a prominent role in the biological
response to melanoma [31]. The increased incidence of
melanoma in the transplant population is likely due to
decreased immune surveillance, although the oncogenic
potential of systemic immunosuppressant medications
may also play a role. Reduced immune surveillance may
also lead to poorer outcomes in melanoma arising pre-
and post-transplant, but clinical data are limited. Late
transmission of donor melanoma after up to 32 years of
melanoma-free survival in the host suggests that immuno-
suppression can promote activation of previously dormant
melanoma cells [32]. Melanoma regression with removal
of immunosuppression has also been described [33], and
many of the systemic treatments for metastatic melanoma
are immune-activating therapies [34].
In transplant candidates with a history of melanoma, the
risk of post-transplant recurrence and metastasis has im-
portant implications for the decision to pursue transplant-
ation. The quality of data available to guide this decision is
currently limited to uncontrolled, non-population-based
reports that lack staging information. Otley et al. proposed
a consensus-based framework of waiting time prior to
consideration of transplantation, based on melanoma
stage [35]. The risks and benefits of pursuing transplant-
ation versus continued dialysis or organ failure in patients
with a history of melanoma need to be weighed on a
case-by-case basis.
Our study has several limitations. Firstly, our review is
limited by the quality of the included studies. Only oneincidence study adjusted the melanoma rates for race, an
important risk factor for skin cancer [19]. This could
affect the estimates of relative risk if the racial compos-
ition differed between transplant and general popula-
tions. Data on the level of immunosuppression were also
not available for the identified studies, with inevitable
heterogeneity of medications and dosing within each
transplant population and between studies. Furthermore,
staging information was uniformly lacking, which pre-
cluded evaluation of the severity of melanoma at the time
of diagnosis in the transplant population versus the
general population, and the impact of stage on melanoma
outcomes. Finally, the overall heterogeneity of the inclu-
ded incidence studies was moderate, as reflected by the
I-squared value of 46%. We explored two potential sources
of heterogeneity and found that the graft type and cohort
year accounted for all of the between-study variability.
Conclusion
Our systematic review found that there is a 2.4-fold
increased incidence of melanoma in the transplant
population compared to the general population. Non-
population-based data suggest a worse prognosis for
late-stage melanoma developing in the transplant popula-
tion versus the general population. These findings have
several implications for clinical practice and research. The
significantly increased overall risk of melanoma arising
post-transplant means that these patients warrant a multi-
pronged approach to primary and secondary prevention,
including regular full skin examinations for cancer screen-
ing, a low biopsy threshold for suspicious pigmented
lesions, and continual education on the importance of sun
avoidance and protection. Our study has also identified an
important knowledge gap that should be addressed in
future research. Population-based studies that account for
melanoma stage and risk factors are needed for patients
and clinicians to understand better the prognosis of
pre- and post-transplant melanoma. These data would
help to inform treatment decisions, as tumors known
to have a poorer prognosis may require more aggressive
management, including significant reduction or discon-
tinuation of immunosuppression. Robust outcome and
staging data would also help to inform the decision
to pursue, avoid or delay transplantation in patients
with a history of melanoma.
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